Alemtuzumab: The advantages and challenges of a novel therapy in MSMENGE, Til; STÜVE, Olaf; KIESEIER, Bernd C et al.Neurology. 2014, Vol 83, Num 1, pp 87-97, issn 0028-3878, 11 p.Article

AlemtuzumabWEAVER, Timothy A; KIRK, Allan D.Transplantation. 2007, Vol 84, Num 12, pp 1545-1547, issn 0041-1337, 3 p.Article

Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase ultrafiltrationYINHUA WAN; GHOSH, Raja; HALE, Geoff et al.Biotechnology and bioengineering. 2005, Vol 90, Num 3, pp 303-315, issn 0006-3592, 13 p.Article

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathyMARSH, E. A; HIRST, C. L; ROBERTSON, N. P et al.Journal of neurology. 2010, Vol 257, Num 6, pp 913-919, issn 0340-5354, 7 p.Article

Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosisJORDAN, Michael B; MCCLAIN, Kenneth L; XIAOTIAN YAN et al.Pediatric blood & cancer. 2005, Vol 44, Num 3, pp 251-254, issn 1545-5009, 4 p.Article

Effect of alemtuzumab on neoplastic B cells. Editorials, comments and newsGOLAY, Josée; MANGANINI, Massimiliano; RAMBALDI, Alessandro et al.Haematologica (Roma). 2004, Vol 89, Num 12, pp 1415-1420, issn 0390-6078, 14 p.Article

Heterogeneous CD52 expression among hematologic neoplasms : Implications for the use of alemtuzumab (CAMPATH-1H)RODIG, Scott J; ABRAMSON, Jeremy S; PINKUS, Geraldine S et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7174-7179, issn 1078-0432, 6 p.Article

Strategies in the management of alemtuzumab-related side effectsÖSTERBORG, Anders; KARLSSON, Claes; LUNDIN, Jeanette et al.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S29-S35, SUP5Article

AlemtuzumabRAVANDI, Farhad; O'BRIEN, Susan.Expert review of anticancer therapy. 2005, Vol 5, Num 1, pp 39-51, issn 1473-7140, 13 p.Article

Infectious complications associated with alemtuzumab use for lymphoproliferative disordersMARTIN, Stanley I; MARTY, Francisco M; FIUMARA, Karen et al.Clinical infectious diseases. 2006, Vol 43, Num 1, pp 16-24, issn 1058-4838, 9 p.Article

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical TrialCOLES, A. J; FOX, E; MARGOLIN, D. H et al.Neurology. 2012, Vol 78, Num 14, pp 1069-1078, issn 0028-3878, 10 p.Article

Alemtuzumab : infections mortelles = Alemtuzumab and fatal infectionsLa Revue Prescrire. 2008, Vol 28, Num 296, pp 435-435, issn 0247-7750, 1 p.Article

Atypical presentation of varicella zoster in a patient on alemtuzumabVENKATACHALAPATHY, Suresh; CROWE, Josephine; GRAY, Atherton et al.British journal of haematology. 2007, Vol 138, Num 4, issn 0007-1048, 406Article

Adenoviremia Has Limited Clinical Impact in the Majority of Patients Following Alemtuzumab-Based Allogeneic Stem Cell Transplantation in AdultsSIVE, Jonathan I; THOMSON, Kirsty J; MORRIS, Emma C et al.Clinical infectious diseases. 2012, Vol 55, Num 10, pp 1362-1370, issn 1058-4838, 9 p.Article

Alemtuzumab Induction in Renal TransplantationHANAWAY, Michael J; WOODLE, E. Steve; MULGAONKAR, Shamkant et al.The New England journal of medicine. 2011, Vol 364, Num 20, pp 1909-1919, issn 0028-4793, 11 p.Article

Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumabAMBROSE, Lyn R; MOREL, Anne-Sophie; WARRENS, Anthony N et al.Blood. 2009, Vol 114, Num 14, pp 3052-3055, issn 0006-4971, 4 p.Article

Minimal residual disease in chronic lymphocytic leukaemia : is it ready for primetime?NABHAN, Chadi; COUTRE, Steven; HILLMEN, Peter et al.British journal of haematology. 2007, Vol 136, Num 3, pp 379-392, issn 0007-1048, 14 p.Article

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromesZI YI LIM; HO, Aloysius Y. L; INGRAM, Wendy et al.British journal of haematology. 2006, Vol 135, Num 2, pp 201-209, issn 0007-1048, 9 p.Article

Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletionGARLAND, R. J; GROVES, S. J; MARKS, D. I et al.Bone marrow transplantation (Basingstoke). 2005, Vol 36, Num 3, pp 237-244, issn 0268-3369, 8 p.Article

Infection chronique à virus influenza chez un patient traité par alemtuzumab = Persistent influenza virus infection in a patient treated with alemtuzumabBURREL, S; DILHUYDY, S; BOUABDALLAH, K et al.Médecine et maladies infectieuses. 2010, Vol 40, Num 11, pp 657-659, issn 0399-077X, 3 p.Article

CD52 is not a promising immunotherapy target for most patients with multiple myelomaWESTERMANN, Jörg; MASCHMEYER, Georg; VAN LESSEN, Antje et al.International journal of hematology. 2005, Vol 82, Num 3, pp 248-250, issn 0925-5710, 3 p.Article

Alemtuzumab and chronic plaque psoriasisASLAM, A; MARSLAND, A. M; ROG, D et al.British journal of dermatology (1951). 2013, Vol 169, Num 1, pp 184-186, issn 0007-0963, 3 p.Article

The role of alemtuzumab in the management of T-cell malignanciesDEARDEN, Claire.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S44-S52, SUP5Article

Diffuse Alveolar Hemorrhage Following AlemtuzumabSACHDEVA, Ashutosh; MATUSCHAK, George M.Chest. 2008, Vol 133, Num 6, pp 1476-1478, issn 0012-3692, 3 p.Article

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicityNÜCKEL, Holger; FREY, Ulrich H; RÖTH, Alexander et al.European journal of pharmacology. 2005, Vol 514, Num 2-3, pp 217-224, issn 0014-2999, 8 p.Article